-
Featured
Prevalence of Anaphylaxis Increasing in U.S. Infants and Toddlers
Massachusetts General Hospital researchers, Lacey B. Robinson, MD, MPH, and Carlos A. Camargo, Jr., MD, DrPH, found that between 2006 and 2015 in the U.S., emergency department visits for anaphylaxis in infants and toddlers more than doubled while hospitalizations declined.
-
Novel Schema Classifies Allergy-related Safety Events in Healthcare Settings
Researchers at Massachusetts General Hospital analyzed 299,031 safety reports and identified 744 allergy-related safety events they used to create a novel allergy safety event classification schema. With further development, it could be used to reduce patient exposure to known allergens in healthcare settings.
-
Hospitalized Pneumonia Patients Who Have Unconfirmed Penicillin/Cephalosporin Allergy Likely to Receive Suboptimal Treatment
Kimberly Blumenthal, MD, MSc, of the Division of Rheumatology, Allergy and Immunology, and colleagues found that inpatients with pneumonia who have an allergy to penicillin or cephalosporin recorded in their charts were less likely to receive a guideline-indicated beta-lactam antibiotic than those without it noted.
-
Discovering the Pathways That Lead to Allergic Asthma
Jehan Alladina, MD, and colleagues of the Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital, are using an innovative in vivo research method to study allergic asthma pathogenesis.
-
Severe Allergic Reactions Are Rare with COVID-19 mRNA Vaccines
A prospective study of employee mRNA COVID-19 vaccination at Mass General Brigham linked self-reported history of high-risk allergy to increased risk of self-reported allergic reactions, but only 0.3% of employees had severe reactions and the vast majority completed the two-dose series.
-
Key Allergic Mediators of Eosinophilic Esophagitis Identified
Massachusetts General Hospital researchers have provided insight into the mechanisms that drive inflammation in eosinophilic esophagitis, including a novel pathway that may lead to recruitment of pathogenic effector T helper 2 cells to the esophagus and how these cells mediate eosinophilic inflammation.
Allergy Contributors
-
Carlos A. Camargo Jr., MD, DrPH
Conn Chair in Emergency Medicine, Department of Emergency Medicine, Massachusetts General Hospital, Founder and Division Chief, Emergency Medicine Network, Professor of Emergency Medicine, Harvard Medical School
Recent Article
Acid Suppressant Therapy in Infancy Linked to Increased Risk of Childhood Respiratory Conditions -
Kimberly G. Blumenthal, MD, MSc
Quality and Safety Officer for Allergy, Co-Director, Clinical Epidemiology Program, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Novel Schema Classifies Allergy-related Safety Events in Healthcare Settings
-
Robert M. Anthony, PhD
Principal Investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Recent Article
Sialylation of IgE Is a Marker of Allergic Pathogenicity, Suggests New Treatment Approach -
Rochelle P. Walensky, MD, MPH
Former Chief, Division of Infectious Diseases, Professor of Medicine, Harvard Medical School, Steve and Deborah Gorlin MGH Research Scholar
Recent Article
COVID-19 Vaccines: Proper Implementation as Important as Efficacy
-
Wayne G. Shreffler, MD, PhD
Chief, Pediatric Allergy & Immunology, Director, Food Allergy Center, Principal Investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital
Recent Article
Key Allergic Mediators of Eosinophilic Esophagitis Identified
Rheumatology, Allergy and Immunology
The Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital provides leading-edge treatment and transformative care to patients with rheumatic disease and autoimmune conditions.